GlassScriptPhysician profile
Marvin J Young
NPI 1235221219
$8,449.88
in general payments reported to CMS, 2019-2025
54 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,990 · 2020: $999 · 2021: $749 · 2022: $1,211 · 2023: $1,150 · 2024: $1,127 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.78 |
| Education | $157.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,204.53 | 2019-2025 | Spaceoar Vue System - 10ml, Rezum Generator |
| Janssen Biotech, INC. | $881.93 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Astellas Pharma US INC | $783.50 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $736.76 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $648.08 | 2020-2025 | Myrisk, Prolaris, Precisetumor |
| Endo Pharmaceuticals INC. | $623.48 | 2019-2023 | Aveed, Xiaflex |
| Medtronic, INC. | $592.95 | 2021-2024 | Interstim |
| Merck Sharp & Dohme LLC | $270.23 | 2022-2024 | Lynparza, Keytruda, Welireg |
| Medtronic USA, INC. | $215.38 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $202.60 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $168.26 | 2020-2025 | |
| Antares Pharma, INC. | $148.83 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Abbvie INC. | $148.64 | 2023-2025 | Botox |
| Urogen Pharma, INC. | $137.72 | 2021-2025 | Jelmyto |
| Endo USA, INC. | $124.54 | 2024-2025 | Xiaflex, Aveed |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.